J&J DARZALEX® (daratumumab) subcutaneous positive EU panel opinion for multiple myeloma

 If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundational therapy in the frontline setting. 

Recommendation supported by results from CEPHEUS, the fifth Phase 3 study of daratumumab to demonstrate improved progression free survival in the frontline setting

https://www.globenewswire.com/news-release/2025/2/28/3034707/0/en/Johnson-Johnson-s-DARZALEX-daratumumab-subcutaneous-based-regimen-receives-positive-CHMP-opinion-for-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibi.html